EGFR and non-small cell lung carcinoma: Although our meta-analysis revealed that skin rash was an efficient factor for predicting the response rate, PFS and OS of patients with NSCLC treated with an EGFR-TKI, skin rash can affect the patient quality of life, leading to dose reduction or even discontinuation, which may affect patient outcome.